Lee Jordan

01382 632920
Honorary Senior Clinical Lecturer (University of Dundee), Associate Medical Director for Access & Assurance (NHS Tayside), Consultant Cellular Pathologist (NHS Tayside), CMO’s Specialty Adviser for Cellular Pathology (CMO Office – Scotland).



Lee Jordan studied Medicine at the University of Edinburgh between 1991 and 1997. He also received a Medical Research Council Scholarship to study for an intercalated degree and graduated with a first class honours in Genetics (B.Sc.(Hons)) in 1996. Completion of his primary medical degree (M.B.,Ch.B.) followed in 1997.

Following clinical posts in Edinburgh and Dundee, Dr Jordan embarked upon his cellular pathology training in Edinburgh and became a Clinical Lecturer at Edinburgh University. Following achievement of the M.R.C.Path by examination, he spent a sabbatical at the University of Chicago (2003), completing training in 2004.

Dr Jordan was then appointed as a Consultant Cellular Pathologist with a specialist interest in Breast Pathology by NHS Tayside in 2004. He was also appointed as an Honorary Senior Clinical Teacher at that time and was promoted to an Honorary Senior Clinical Lecturer in 2011.

During his substantive career, Dr Jordan has been the Clinical Lead for NHS Tayside Pathology (2007-2013), the Clinical Lead for the Scottish (Cellular) Pathology Network (2013-2016), interim Clinical Director for Specialist Services (2018) and is the current Associate Medical Director for the Access & Assurance Clinical Care Division of NHS Tayside. He is also the current Speciality Adviser to the Scottish Chief Medical Officer for Cellular Pathology (2013 to date).

His research interests pertain to the pathological aspects of breast cancer and he conducts collaborative translational research alongside clinical trials activity and correlative studies with other imaging modalities including radiological imaging and computational imaging.



NHS Tayside

Associate Medical Director for Access & Assurance – 2018 to date.

‘Discovery Champion’ – 2016 to date.

Interim Clinical Director for Specialist Services – 2018.

Chair of the pilot Primary & Secondary Care Interface Group (PSCIG) – 2017.

Clinical Lead for Cellular Pathology (Histopathology & Cytopathology) – 2007-2013.

Invited Member of the Scottish (Cellular) Pathology Network (SPAN) – 2007-2013.

Invited Member of the Cancer Overview Group – 2007-2013.

Consultant Appraiser – 2007-2010.

Lead Consultant for Histopathology – 2005-2007.

University of Dundee

Invited Member of the Tayside Tissue Bank (now Tayside Biorepository) Access Committee – 2007-2018.

Invited Member of the Tayside Tissue Bank (now Tayside Biorepository) Management Committee – 2010-2016.

Invited member of the Cancer Informatics DECIPHER and Demonstrator project – 2011-2013.

Member of the National Breast Cancer Campaign Tissue Bank Operations Group – 2009-2011.

University of Edinburgh

Membership of the University of Edinburgh Senatus Academicus – 2003-2004.

Trainee representative to the local South East Scotland Histopathology and Laboratory Medicine Training committees – 2001-2003.



Scottish Government Healthcare and Social Care Directorate

Scottish Chief Medical Officer’s (CMO) Specialty Adviser for Cellular Pathology 2013 to date.

Invited Member of the Scottish Medical and Scientific Advisory Committee (SMASAC) – 2013-2016.

NHS Scotland National Specialist Services – National Services Division

Lead Clinician for the Scottish (Cellular) Pathology Network (SPAN) – 2013-2016.

Invited Member of the Molecular Pathology Consortium Steering Group – 2013-2016.

Invited Member of the Diagnostics Steering Group – 2013-2016.

Invited Member of the Molecular Pathology Evaluation Panel – 2012-2013.

Invited member of the Scotland & Northern Ireland EQA Scheme Management Committee – 2006-2008.

Breast Cancer Now Tissue Bank

Grant holder and co-creator – 2009-2015.

Member of the Tissue Bank Operations Group – 2009-2011.

Member of the Access Committee – 2011-2015.


Royal College of Pathologists

Elected Member of the Scottish Regional Council – 2005-2008.

Scottish trainee representative to the Trainee Advisory Committee (TAC) – 2001-2003.

TAC Representative to the Specialty Advisory Committee on Histopathology – 2001-2003.

TAC Representative to the Scottish Regional Council – 2001-2003.



University of Chicago & The American Association of Pathologists’ Assistants

Invited Lecture and Workshop – 2004.



Peer review for scientific journals; local/national/international clinical trials work.


Lee Jordan is a full-time consultant and all research is carried out in addition to his clinical, administrative and leadership activities.

He has published scientific works that have been cited more than 3,500 times, 2,600 of these citations were in the past five years.

He has been awarded grants totalling more than £9 million.

His research has been presented nationally and internationally at numerous scientific meetings including:

  • The San Antonio Breast Cancer Symposium (SABCS)
  • American Society of Clinical Oncology (ASCO)
  • American Association for Cancer Research (AACR)
  • Radiological Society of North America (RSNA)
  • American Society of Human Genetics (ASHG)
  • Institute of Electrical and Electronics Engineers (IEEE)
  • Medical Image Computing and Computer Assisted Intervention (MICCAI)
  • National Cancer Research Institute (NCRI)
  • European Breast Cancer Conference (EBCC)
  • IMPAKT Breast Cancer Conference
  • European Organisation for Research and Treatment of Cancer (EORTC)
  • International Society for Biological and Environmental Repositories (ISBER)
  • Pathological Society of Great Britain & Ireland
  • British Society of Breast Radiology
  • European Congress of Radiology
  • Society for Mathematical Biology
  • British Breast Group


Only the peer reviewed articles published over the past five years (2014-2018) are presented:

  1. Evans A, Whelehan P, Thompson A, Purdie CA, Jordan LB, Macaskill J, Waugh S, Fuller-Pace F, Brauer K, Vinnicombe S. Prediction of pathological complete response to neoadjuvant chemotherapy for primary breast cancer comparing interim ultrasound, shear wave elastography and MRI. Ultraschall in Med 2018; 39(4): 422-431.
  2. Yeap PM, Evans A, Purdie CA, Jordan LB, Vinnicombe SJ. A comparison of the imaging features of pleomorphic and classical invasive lobular carcinoma. Breast Cancer Res Treat 2018; 172(2): 381-389.
  3. Ahmeidat H, Purdie C, Jordan L, Fleming D, McCullough J, Evans A. Non-histopathological parameters associated with upgrade of breast tumours yielding a core biopsy report of histological grade 2 ductal no special type to grade 3 on excision. Eur J Surg Oncol 2018; 44(11): 1720-1724.
  4. Van Long FN, Lardy-Cleaud A, Bray S, Chabaud S, Dubois T, Diot A, Jordan LB, Thompson AM, Bourdon JC, Perol D, Diaz JJ, Marcel V. Druggable nucleolin identifies breast tumours with poor prognosis that exhibit different biological processes. Cancers 2018; 10(10): 390.
  5. Evans A, Henderson S, Whelehan P, Purdie C, Jordan L, Thompson A, Vinnicombe S. Identification of pathological complete response after Neoadjuvant chemotherapy for breast cancer: comparison of greyscale ultrasound, shear wave elastography, and MRI. Clin Radiol 2018; 73(10): 910.
  6. Coulson-Gilmer C, Humphries MP, Rajan SS, Droop A, Jackson S, Condon A, Cserni G, Jordan LB, Jones LJ, Kanthan R, Di Benedetto A, Mottolese M, Provenzano E, Kulka J, Shaaban AM, Hanby AM, Speirs V. Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancer. J Pathol Clin Res 2018; 4: 241-249.
  7. Evans A, Sim YT, Pourreyon C, Thompson A, Jordan L, Fleming D, Purdie C, Macaskill J, Vinnicombe S, Paul Pharoah. Pre-operative stromal stiffness measured by shear wave elastography is independently associated with breast cancer-specific survival. Breast Cancer Res Treat 2018; 171(2): 383-389.
  8. Henderson SA, Gowdh NM, Purdie CA, Jordan LB, Evans A, Brunton T, Thompson AM, Vinnicombe S. Breast cancer: influence of tumour volume estimation method at MrI on prediction of pathological response to neoadjuvant chemotherapy. Br J Radiol 2018; 91(1087): 20180123.
  9. Littlejohn LA, Gibbs J, Jordan LB, Miedzybrodzka ZH, Bell C, Goudie D, Dunlop J, Berg JN. Assessing the effectiveness of NICE critierial for stratifying breast cancer risk in a UK cohort. Eur J Human Genet 2018; 26(4): 599-603.
  10. Moss RM, Amin A, Crews C, Purdie CA, Jordan LB, Iacoviello F, Evans A, Speller R, Vinnicombe S. Correlation of X-ray diffraction signatures of breast tissue and their histopathological classification. Sci Rep 2017; 7: 12998.
  11. Humphries MP, Rajan SS, Honarpisheh H, Cserni G, Dent J, Fulford L, Jordan LB, Jones JL, Kanthan R, Litwiniuk M, Di Benedetto A, Mottolese M, Provenzano E, Shousha S, Stephens M, Kulka J, Ellis IO, Titloye AN, Hanby AM, Shaaban AM, Speirs V. Characterisation of male breast cancer: a descriptive biomarker study from a large patient series. Sci Rep 2017; 28(7): 45293.
  12. Humphries MP, Sundara Rajan S, Droop A, Suleman C, Carbone C, Nilsson C, Honarpisheh H, Cserni G, Dent J, Fulford L, Jordan LB, Jones JL, Kanthan R, Litwiniuk M, Di Benedetto A, Mottolese M, Provenzano E, Shousha S, Stephens M, Walker RA, Kulka J, Ellis IO, Jeffery M, Thygesen HH, Cappelletti V, Daidone MG, Hedenfalk IA, Fjällskog ML, Melisi D, Stead L, Shaaban A, Speirs V. A case matched gender comparison transcriptomic screen identifies eIF4E and eIF5 as potential prognostic and tractable biomarkers in male breast cancer. Clin Cancer Res 2017; 23(10): 2575-2583.
  13. Hadad SM, Jordan LB, Roy PG, Purdie CA, Iwamoto T, Pusztai L, Moulder-Thompson SL, Thompson AM. A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer. BMC Cancer 2016; 16:745.
  14. Gadea G, Arsic N, Fernandes K, Diot A, Joruiz SM, Abdallah S, Meuray V, Vinot S, Anguille C, Remenyi J, Khoury MP, Quinlan PR, Purdie CA, Jordan LB, Fuller-Pace FV, de Toledo M, Cren M, Thompson AM, Bourdon JC, Roux P. TP53 drives invasion through expression of its Δ133p53β variant. eLife 2016: e14734.
  15. Evans A, Purdie CA, Jordan L, Macaskill EJ, Flynn J, Vinnicombe S. Stiffness at shear-wave elastography and patient presentation predicts upgrade at surgery following an ultrasound-guided core biopsy diagnosis of ductal carcinoma in situ. Clin Radiol 2016: 1156-1159.
  16. Giannotti E, Vinnicombe SJ, Whelehan P, Thomson K, McLean D, Purdie C, Jordan L, Evans A.  Shear wave elastography and grey scale assessment of palpable probably benign masses: is biopsy always required? Br J Radiol 2016: 89(1062): 20150865.
  17. Evans A, Sim Y-T, Thomson K, Jordan L, Purdie C, Vinnicombe SJ. Shear Wave Elastography of breast cancer: sensitivity according to histological type in a large cohort. The Breast 2016; 26: 115-118.
  18. Waugh SA, Purdie CA, Jordan LB, Vinnicombe A, Lerskit RA, Martin P, Thompson AM. Magnetic resonance imaging texture analysis classification of primary breast cancer. Eur Radiol 2016(2); 322-330.
  19. Quinlan PR, Groves M, Jordan LB, Stobart H, Purdie CA, Thompson AM. The Informatics Challenges Facing Biobanks: A Perspective from a United Kingdom Biobanking Network. Biopreserv Biobank 2015: 13(5); 363-370.
  20. Akbar S, Jordan LB, Purdie CA, Thompson AM, McKenna SJ. Comparing computer-generated and pathologist-generated tumour segmentations for immunohistochemical scoring of breast tissue microarrays. Br J Cancer 2015; 113(7); 1075-1080.
  21. Marcar L, Ihrig B, Hourian J, Bray SE, Quinlan PR, Jordan LB, Thompson AM, Hupp TR, Meek DW. MAGE-A cancer/testis antigens inhibit MDM2 ubiquitylation function and promote increased levels of MDM4. PLOS One 2015; 10(5): e0127713.
  22. Lin M-L, Patel H, Remenyl J, Banerji CRS, Lai C-F, Periyasamy M, Lombardo Y, Busonero C, Ottaviani S, Passey A, Quinlan PR, Purdie CA, Jordan LB, Thompson AM, Finn RS, Rueda OM, Caldas C, Gil J, Coombes RC, Fuller-Pace FV, Teschendorff AE, Buluwela L, Ali S. Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancer. Oncotarget 2015; 6(25), 21685-21703.
  23. Hadad SM, Coates P, Jordan LB, Dowling RJO, Chang MC, Done SJ, Purdie CA, Goodwin PJ, Stambolic V, Moulder-Thompson S, Thompson AM. Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window
of opportunity randomized trial. Breast Cancer Res Treat 2015; 150(1): 149-155.
  24. Downey CL, Simpkins SA, White J, Holliday DL, Jones JL, Jordan LB, Kulka J, Pollock A, Rajan SS, Thygesen HH, Hanby AM, Speirs V. Response to: comment on,‘Tumour-stroma ratio (TSR) in oestrogen-positive breast cancer patients’. Br J Cancer 2014;            112(11): 1833-1834.
  25. Moore KM, Thomas GJ, Duffy SW, Warwick J, Gabe R, Chou P, Ellis IO, Green AR, Haider S, Bruilette K, Saha A, Vallath S, Bowen R, Chelala C, Eccles D, Tapper WJ, Thompson AM, Quinlan P, Jordan L, Gillett C, Brentall A, Violette S, Weinreb PH, Kendrew J, Barry ST, Hart IR, Jones JL, Marshall JF. Therapeutic targeting of integrin αvβ6 in Breast cancer. J Natl Cancer Inst 2014; 106(8): pii: dju169.
  26. Bouchalova P, Nenutil R, Muller P, Hrstka R, Appleyard M, Murray K, Jordan LB, Purdie CA, Quinlan P, Thompson AM, Vojtesek B, Coates PJ. Mutant p53 accumulation in human breast cancer is not an intrinsic property nor dependent on structural or functional disruption but is regulated by exogenous stress and receptor status. J Pathol 2014; 233: 238-246.
  27. Downey CL, Simpkins SA, White J, Holliday DL, Jones JL, Jordan LB, Kulka J, Pollock A, Rajan SS, Thygesen HH, Hanby AM, Speirs V. The prognostic significance of tumour–stroma ratio in oestrogen receptor-positive breast cancer. Br J Cancer 2014; 110; 1744-1747.
  28. Vinnicombe S, Whelehan P, Thomson K, McLean D, Purdie CA, Jordan LB, Hubbard S, Evans AJ. What are the characteristics of breast cancers misclassified as benign by quantitative ultrasound shear wave elastography? Eur Radiol 2014; 24(4): 921-926.
  29. Purdie CA, Quinlan P, Jordan LB, Ashfield A, Ogston S, Dewar JA, Thompson AM. Progesterone receptor expression is an independent prognostic variable in early breast cancer – a population-based study. Br J Cancer 2014; 110: 565-572.
  30. Evans A, Rauchhaus P, Whelehan P, Thomson K, Purdie CA, Jordan LB, Michie CO, Thompson A, Vinnicombe S. Does shear wave ultrasound independently predict axillary lymph node metastasis in women with invasive breast cancer? Breast Cancer Res Treat 2014; 143(1): 153-157.
  31. Province MA, Goetz MP, Brauch H, Flockhart JA, Hebert JM, Whaley R, Suman VJ, Schroth V, Winter S, Zembutsu H, Mushiroda T, Newman WG, Lee M-T M,  Ambrosone CB, Beckmann MW, Choi J-Y, Dieudonné A-S, Fasching PA, Ferraldeschi R, Gong L, Haschke-Becher E, Howell A, Jordan LB, Hamann U, Kiyotani K, Krippl P, Lambrechts D, Latif A, Langsenlehner U, Lorizio W, Neven P, Nguyen AT, Park B-W, Purdie CA, Quinlan P, Renner W, Schmidt M, Schwab M, Shin J-G, Stingl JC, Wegman P, Wingren S, Wu AHB, Ziv E, Zirpoli G, Thompson AM, Jordan VC, Nakamura Y, Altman RB, Ames MM, Weinshilboum RM, Eichelbaum M, Ingle JN, Klein TE. CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-analysis of Heterogeneous Study Populations. Clinical Pharmacology & Therapeutics 2014; 95(2): 216-227.




He was invited to lecture to the American Association of Pathologists’ Assistants in Chicago in 2004 regarding the UK experience of autopsy pathology in light of the then recent organ retention scandal.


He has been invited to lecture both medical and non-medical staff across Scotland in relation to his national roles and also for post-graduate training. He has also contributed to the examination work of the R.C.Path.


He has contributed to local undergraduate medical education in relation to general pathology, cardiovascular pathology, breast pathology and human genetics. He has also provided post-graduate teaching and mentoring for non-medical staff undergoing medical role extension training and has provided secondary level supervision for M.D. and Ph.D. students.